Neumora Therapeutics NMRA
NASDAQ NMRA
$0.47 +0.01 (+1.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Neumora Therapeutics (NMRA) Preferred Stock Liabilities (2022 - 2023)

Updated

Neumora Therapeutics' Preferred Stock Liabilities came in at $843.69 million for Q2 2023, unchanged from the prior quarter.

Analysis

Neumora Therapeutics (NMRA) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends

Going back to Q3 2022, Neumora Therapeutics' Preferred Stock Liabilities data covers 4 quarters.

  • Business Quant data shows NMRA's Preferred Stock Liabilities at $843.69 million (Q1 2023), $843.69 million (Q4 2022) and $817.1 million (Q3 2022) in the three quarters before Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Neumora Therapeutics 88.31 Mn -529.65 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 843.69 Mn
Mar 31, 2023 843.69 Mn
Dec 31, 2022 843.69 Mn
Sep 30, 2022 817.10 Mn
API Access

Neumora Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=NMRA&period=max&api_key=YOUR_API_KEY